Dr. Scott Antonia, MD
Claim this profileDuke University
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
2 reported clinical trials
5 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage I
Stage II
2Non-Small Cell Lung Cancer
ALK positive
NTRK positive
MET positive
Affiliated Hospitals
Clinical Trials Scott Antonia, MD is currently running
Evolocumab + Immunotherapy
for Lung Cancer
This is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer). Nivolumab (Opdivo™) and ipilimumab (Yervoy™) are immunotherapy-type drugs which are approved for the treatment of advanced lung cancer that has expression of PD-L1 greater than or equal to 1%. Evolucumab is being combined with nivolumab and ipilimumab to see if it will improve the anti-tumor capabilities of the immunotherapy. Adding evolocumab to the combination of nivolumab and ipilimumab has not been tested in people before and is considered investigational.
Recruiting1 award Phase 212 criteria
PCSK9 + PD-1 Inhibitors
for Non-Small Cell Lung Cancer
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.
Recruiting1 award Phase 28 criteria
More about Scott Antonia, MD
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Scott Antonia, MD has experience with
- Evolocumab
- Ipilimumab
- Nivolumab
- Alirocumab
- Cemiplimab
Breakdown of trials Scott Antonia, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Antonia, MD specialize in?
Scott Antonia, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage I.
Is Scott Antonia, MD currently recruiting for clinical trials?
Yes, Scott Antonia, MD is currently recruiting for 2 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Scott Antonia, MD has studied deeply?
Yes, Scott Antonia, MD has studied treatments such as Evolocumab, Ipilimumab, Nivolumab.
What is the best way to schedule an appointment with Scott Antonia, MD?
Apply for one of the trials that Scott Antonia, MD is conducting.
What is the office address of Scott Antonia, MD?
The office of Scott Antonia, MD is located at: Duke University, Durham, North Carolina 27705 United States. This is the address for their practice at the Duke University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.